Zacks Research cut shares of Repligen (NASDAQ:RGEN – Free Report) from a strong-buy rating to a hold rating in a research report sent to investors on Monday,Zacks reports.
RGEN has been the subject of a number of other reports. Evercore reaffirmed an “outperform” rating and issued a $160.00 price objective on shares of Repligen in a research report on Monday, July 6th. Wolfe Research began coverage on Repligen in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 target price on the stock. Benchmark raised Repligen from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a report on Tuesday, July 7th. HSBC decreased their price target on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Finally, UBS Group reiterated a “buy” rating on shares of Repligen in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and an average target price of $168.57.
View Our Latest Stock Report on RGEN
Repligen Price Performance
Repligen (NASDAQ:RGEN – Get Free Report) last posted its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.09. The firm had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business’s revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.26 EPS. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, analysts forecast that Repligen will post 2.06 EPS for the current fiscal year.
Institutional Trading of Repligen
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. QRG Capital Management Inc. increased its position in shares of Repligen by 14.6% during the second quarter. QRG Capital Management Inc. now owns 3,550 shares of the biotechnology company’s stock valued at $484,000 after buying an additional 451 shares during the period. Envestnet Portfolio Solutions Inc. increased its holdings in Repligen by 24.5% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 10,251 shares of the biotechnology company’s stock worth $1,399,000 after acquiring an additional 2,019 shares during the period. Tidal Investments LLC increased its holdings in Repligen by 75.2% during the 2nd quarter. Tidal Investments LLC now owns 8,863 shares of the biotechnology company’s stock worth $1,209,000 after acquiring an additional 3,803 shares during the period. Engineers Gate Manager LP lifted its stake in Repligen by 146.0% in the 2nd quarter. Engineers Gate Manager LP now owns 7,646 shares of the biotechnology company’s stock worth $1,043,000 after purchasing an additional 4,538 shares in the last quarter. Finally, Waverly Advisors LLC lifted its stake in Repligen by 10.1% in the 2nd quarter. Waverly Advisors LLC now owns 32,751 shares of the biotechnology company’s stock worth $4,469,000 after purchasing an additional 3,009 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.
Repligen Company Profile
Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.
The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.
Recommended Stories
- Five stocks we like better than Repligen
- Bitcoin Is Bouncing Back—Here are 2 Ways to Play the Rebound
- The Bull Case for Amprius Technologies Just Got Stronger
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
